RxDoctor Payments Data

Miranda Renfrow, DO

Ophthalmology · Saint Johnsbury, VTNPI 1598915332

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.

$313in general payments, 2019–2025

Across 12 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$65
  • Sight Sciences, Inc.$63
  • Glaukos Corporation$39
  • Alcon$37
  • Rayner Intraocular Lenses Limited$32
  • Astellas Pharma US Inc$23
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$313 in reported general payments places this provider in the 75th percentile of 35 ophthalmology providers in Vermont.

See all ophthalmology providers in Vermont

Medicare billing

Part B allowed, 2024
$1,683
Medicare patients
14
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost16$7,327
Latanoprost265$2,879
CombiganBrimonidine Tartrate/Timolol11$2,003
Prednisolone Acetate50$1,499
Timolol Maleate126$1,067
Fluorometholone17$889
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat52$812
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha44$577
ErythromycinErythromycin Base28$355
Dorzolamide Hcl11$259
Brimonidine Tartrate29$246
Doxycycline Hyclate28$202
Ofloxacin11$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$65$9,33027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 ophthalmology providers in Vermont.

Other ophthalmology in Saint Johnsbury

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →